Clinical Trials Logo
  1. Home
  2. Colorectal Tumors
  3. NCT02399059

Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome

Colorectal Tumors Clinical Trial

Official title:
Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution During Elective Colorectal Cancer Surgery on the Oncologic Outcome

Clinical Trial Summary

Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, leaving unattended the neoplasm. It has been described that SSI may result in a worse oncologic outcome.

Clinical Trial Description

Antibiotics combined with lavage have demonstrated a reduction in the bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, as immunologic defense is focused on controlling the septic focus, leaving unattended the neoplasm. It has been described that SSI may result in a worse oncologic outcome. The aim of this study is to evaluate prospectively the effect of peritoneal lavage with clindamycin and gentamicin on the oncologic outcome of colorectal tumours. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02399059
Study type Interventional
Source Hospital General Universitario Elche
Contact
Status Completed
Phase Phase 3
Start date January 2011
Completion date March 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT00704600 - Nelfinavir, a Phase I/Phase II Rectal Cancer Study Phase 1/Phase 2
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT01545141 - Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Phase 1/Phase 2
Withdrawn NCT01157039 - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin Phase 2
Completed NCT03428958 - A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Phase 1/Phase 2
Completed NCT01291420 - Dendritic Cell Vaccination for Patients With Solid Tumors Phase 1/Phase 2
Completed NCT00478634 - A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer Phase 1
Completed NCT05484687 - Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors N/A
Completed NCT01139138 - Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer Phase 1/Phase 2
Completed NCT01671592 - Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) Phase 1
Recruiting NCT05136092 - A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors N/A
Active, not recruiting NCT03377361 - An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Phase 1/Phase 2
Completed NCT01793207 - Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population N/A
Completed NCT04166383 - VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Phase 2
Completed NCT02347735 - Predictive Factors for Anastomotic Leakage After Colorectal Surgery
Active, not recruiting NCT01675128 - ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer Phase 1/Phase 2
Terminated NCT03050814 - Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 Phase 2